Cancer combination therapy comprising azd2171 and imatinib

Details Cancer combination therapy comprising azd2171 and imatinib Cancer combination therapy comprising azd2171 and imatinib

A - Human Necessities

61

K

A61K 31/506 (2006.01) A61K 31/517 (2006.01) A61P 35/00 (2006.01) A61P 35/02 (2006.01)

Patent

CA 2579067

The present invention relates to a method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionizing radiation, particularly a method for the treatment of a cancer, particularly a cancer involving a solid tumor or a leukaemia, which comprises the administration of AZD2171 in combination with imatinib; to a pharmaceutical composition comprising AZD2171 and imatinib; to a combination product comprising AZD2171 and imatinib for use in a method of treatment of a human or animal body by therapy; to a kit comprising AZD2171 and imatinib; to the use of AZD2171 and imatinib in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionizing radiation.

La présente invention concerne un procédé destiné à produire un effet antiangiogénique et/ou un effet de réduction de la perméabilité vasculaire chez un animal à sang chaud tel qu'un être humain, qui est éventuellement traité par rayonnements ionisants, en particulier une méthode de traitement d'un cancer, en particulier un cancer impliquant une tumeur solide ou une leucémie, qui comprend l'administration de AZD2171 en association avec l'imatinib ; une composition pharmaceutique comprenant AZD2171 et l'imatinib ; un produit combiné comprenant AZD2171 et l'imatinib à utiliser dans une méthode de traitement d'un corps humain ou animal par une thérapie; un kit comprenant AZD2171 et l'imatinib; l'utilisation de AZD2171 et de l'imatinib dans la fabrication d'un médicament utilisé pour produire un effet antiangiogénique et/ou un effet de réduction de la perméabilité vasculaire chez un animal à sang chaud tel qu'un être humain, qui est éventuellement traité par rayonnements ionisants.

Affiliated with

Also associated with

Rating

Cancer combination therapy comprising azd2171 and imatinib does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cancer combination therapy comprising azd2171 and imatinib, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cancer combination therapy comprising azd2171 and imatinib will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1529112